Sotabase

Career

· Associate Professor, UMC Utrecht2022–
· Principal Investigator, Center for Molecular Medicine UMC Utrecht (Current)2019–
· Postdoctoral Researcher, UMC Utrecht2014–2022

Publications (279)

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Blood · 2014
852
cited
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Journal of Clinical Oncology · 2010
239
cited
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Blood · 2021
167
cited
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
Blood Advances · 2020
142
cited
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Journal of Clinical Oncology · 2003
136
cited
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
Blood Advances · 2021
112
cited
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease
Clinical Cancer Research · 2004
98
cited
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Journal of Clinical Oncology · 2004
98
cited
Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma
1991
98
cited
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
Blood · 2012
92
cited
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
Journal of Clinical Oncology · 2009
91
cited
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
Journal of Clinical Oncology · 2008
87
cited
Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center
British Journal of Haematology · 2016
84
cited
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Blood Advances · 2020
82
cited
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Blood · 2017
75
cited
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Blood · 2012
75
cited
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Blood · 2002
63
cited
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Blood · 2013
63
cited
Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas.
Annals of Oncology · 1994
62
cited
Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.
2010
54
cited
Sotabase
Maria Rodriguez | Researcher Profile | Sotabase | Sotabase